These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35201318)

  • 1. Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment.
    Sidiropoulos DN; Rafie CI; Jang JK; Castanon S; Baugh AG; Gonzalez E; Christmas BJ; Narumi VH; Davis-Marcisak EF; Sharma G; Bigelow E; Vaghasia A; Gupta A; Skaist A; Considine M; Wheelan SJ; Ganesan SK; Yu M; Yegnasubramanian S; Stearns V; Connolly RM; Gaykalova DA; Kagohara LT; Jaffee EM; Fertig EJ; Roussos Torres ET
    Cancer Immunol Res; 2022 May; 10(5):656-669. PubMed ID: 35201318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
    Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET
    Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
    Orillion A; Hashimoto A; Damayanti N; Shen L; Adelaiye-Ogala R; Arisa S; Chintala S; Ordentlich P; Kao C; Elzey B; Gabrilovich D; Pili R
    Clin Cancer Res; 2017 Sep; 23(17):5187-5201. PubMed ID: 28698201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors.
    Hashimoto A; Fukumoto T; Zhang R; Gabrilovich D
    Cancer Immunol Immunother; 2020 Sep; 69(9):1929-1936. PubMed ID: 32435850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
    Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
    Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
    Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
    Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entinostat induces antitumor immune responses through immune editing of tumor neoantigens.
    Truong AS; Zhou M; Krishnan B; Utsumi T; Manocha U; Stewart KG; Beck W; Rose TL; Milowsky MI; He X; Smith CC; Bixby LM; Perou CM; Wobker SE; Bailey ST; Vincent BG; Kim WY
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
    Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
    Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
    Smith HJ; McCaw TR; Londono AI; Katre AA; Meza-Perez S; Yang ES; Forero A; Buchsbaum DJ; Randall TD; Straughn JM; Norian LA; Arend RC
    Cancer; 2018 Dec; 124(24):4657-4666. PubMed ID: 30423192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
    Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
    PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
    Chen JS; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Sci Rep; 2022 Jan; 12(1):1100. PubMed ID: 35058524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
    Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy.
    Sarkar OS; Donninger H; Al Rayyan N; Chew LC; Stamp B; Zhang X; Whitt A; Li C; Hall M; Mitchell RA; Zippelius A; Eaton J; Chesney JA; Yaddanapudi K
    Sci Adv; 2023 Jun; 9(26):eadg3736. PubMed ID: 37390211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
    Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
    Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
    Schech A; Kazi A; Yu S; Shah P; Sabnis G
    Mol Cancer Ther; 2015 Aug; 14(8):1848-57. PubMed ID: 26037781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visualization and quantification of
    Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
    Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
    Gatti-Mays ME; Gameiro SR; Ozawa Y; Knudson KM; Hicks KC; Palena C; Cordes LM; Steinberg SM; Francis D; Karzai F; Lipkowitz S; Donahue RN; Jochems C; Schlom J; Gulley JL
    Front Oncol; 2020; 10():581801. PubMed ID: 33747894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma.
    Noonepalle SKR; Gracia-Hernandez M; Aghdam N; Berrigan M; Coulibaly H; Li X; Zevallos-Delgado C; Pletcher A; Weselman B; Palmer E; Knox T; Sotomayor E; Chiappinelli KB; Wardrop D; Horvath A; Shook BA; Lee N; Dritschilo A; Fernandes R; Musunuri K; Shibata M; Villagra A
    J Exp Clin Cancer Res; 2024 Sep; 43(1):263. PubMed ID: 39272209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.